Business Context and Reporting Period
This Form 6-K filing by Check-Cap Ltd. (referred to as Mbody AI Ltd. in metadata) covers the period ending May 22, 2018. The registrant is a foreign private issuer based in Isfiya, Israel, filing under Rule 13a-16 of the Securities Exchange Act of 1934. The report primarily serves to incorporate a press release regarding clinical study results.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report of other information rather than a financial statement.
Material Changes
The material event reported is the publication of CE Mark Multicenter Clinical Study results for the Company's C-Scan® device in the journal Gut. This announcement was made via a press release on May 22, 2018, and is attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or a discussion of risks and contingencies beyond the incorporation of the press release. The document notes that the press release is being incorporated by reference into Post-Effective Amendment No. 1 to Form S-8 (File No. 333-203384) and Form F-3 (File No. 333-211065).
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) to understand the specific clinical outcomes of the C-Scan® study.
- Confirm the regulatory implications of the CE Mark status mentioned in the study results.
- Review the referenced Form S-8 and Form F-3 registration statements for details on capital raising or equity plans linked to this announcement.
- Check subsequent filings for any financial impact resulting from the clinical study publication.